Propanc Biopharma, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2023; fiscal year ends June 30. The filing is unaudited. Although the request metadata says “2022 Q3,” the filing itself covers the quarter ended March 31, 2023.
Business context
Propanc is a development-stage biotechnology company focused on cancer treatments. Its lead candidate, PRP, is a pro-enzyme formulation in preclinical development; the company reported no product sales. It reported 59 granted, allowed, or accepted patents and 17 additional patents filed or under examination.
Financial results and liquidity
| Metric | Three months ended Mar. 31, 2023 | Nine months ended Mar. 31, 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $386,209 | $1,567,043 | $502,181 / $1,391,678 |
| Operating loss | $386,209 | $1,567,043 | $502,181 / $1,391,678 |
| Net loss | $809,809 | $1,912,522 | $462,687 / $1,753,322 |
| Net loss available to common stockholders | $809,809 | $2,321,079 | $700,076 / $2,198,953 |
| Research and development | $66,020 | $242,223 | $50,395 / $147,702 |
At March 31, 2023, cash was $93,241, current assets were $96,575, and current liabilities were $3,060,217, resulting in a $2,963,642 working-capital deficit. Total assets were $143,742, total liabilities $3,085,156, and stockholders’ deficit $2,941,414. Current liabilities included $519,718 of net convertible notes, a $65,280 loan payable, and $132,501 of embedded conversion-option liabilities. Accounts payable and accrued expenses together were about $1.61 million; employee benefit liabilities were $579,888.
For the nine months, operating cash use was $927,278, financing provided $1,013,719, and cash increased by $89,174 to $93,241. Financing included $590,250 of note proceeds and $375,000 from warrant exercises. No meaningful gross margin or operating margin is available because there was no revenue.
Changes and notable items
- Nine-month net loss increased to $1.91 million from $1.75 million; operating expenses rose about $175,000. R&D spending increased about $95,000, which management attributed primarily to University of Jaén research agreements.
- Quarterly net loss rose to $809,809 from $462,687. A $238,367 quarterly loss from changes in derivative fair value, compared with a $165,365 gain in the prior-year quarter, contributed to the increase. The filing describes these valuations as Level 3.
- Common shares outstanding increased from 220.4 million at June 30, 2022 to 2.62 billion at March 31, 2023, largely through conversions of debt and accrued interest. The company also issued 191.999 million shares through alternate cashless warrant exercises. At May 12, 2023, 3.288 billion shares were reported outstanding.
- The company completed a 1-for-1,000 reverse split on May 1, 2023; the filing said FINRA had not yet announced its OTC market effectiveness as of the report date. Subsequent to quarter-end, 667.1 million pre-split shares were issued for note conversions through May 2023.
- Convertible debt financing carries substantial dilution and default risks: several notes have conversion prices tied to discounted market prices, and some provide for default interest, premiums, or penalties. The company reported a default on the Coventry note after missing its first installment due in March 2023.
Outlook, risks, contingencies, and controls
Management stated that available cash was insufficient to meet obligations over the next 12 months and that continued operations depend on additional financing. The filing says recurring losses, operating cash use, the working-capital deficit, and financing dependence raise substantial doubt about the company’s ability to continue as a going concern. No assurance was given that financing would be available on acceptable terms; failure to obtain funding could curtail operations and R&D.
The Crown Bridge loan was past due and in default. The notes disclose $65,280 principal and $30,866 accrued interest at March 31, while the Item 3 disclosure gives $38,281 accrued interest; the filing does not reconcile these figures. The company also disclosed the Coventry installment default. It said it was discussing an extension with the noteholder.
Management reported that disclosure controls were ineffective at March 31, 2023. Continuing material weaknesses included no written internal-control documentation, inadequate segregation of accounting duties, no audit committee, and insufficient financial-reporting review and U.S. GAAP expertise. Proposed remediation depends in part on raising capital.
Other items include a related-party office lease and significant accrued related-party rent, as well as a media-services consulting agreement with a stock component targeting 9.9% ownership. The CEO’s annual salary was increased to A$600,000 effective July 1, 2022. The filing reported no material pending litigation; it disclosed an accrued $30,000 IRS penalty plus interest for late historical filings.
Investor verification priorities
- Confirm current cash runway, financing availability, and the status of the company’s going-concern plans.
- Reconcile the Crown Bridge accrued-interest amounts and confirm the status, balances, and cure or extension terms for the Crown Bridge and Coventry defaults.
- Review current post-reverse-split shares outstanding, conversions, warrant terms, reserved shares, and potential dilution from convertible debt.
- Confirm FINRA/OTC processing of the reverse split and the current trading status of the common stock.
- Assess progress, funding, and timelines for PRP’s preclinical program and the University of Jaén research agreement.
- Track remediation of the disclosed internal-control weaknesses and review related-party compensation, rent, and consulting arrangements.